The Goal

Preserving Synaptic Connections

At Allyx Therapeutics, our focus is on targeting the underlying mechanisms of synapse loss in Alzheimer’s disease. By protecting these critical pathways, we aim to preserve the cognitive functions that define who we are.

An Innovative Approach to Synapse Protection

Stabilizing the Neuronal Network

Allyx Therapeutics is pioneering a clinical-stage approach that targets the underlying mechanisms of synaptic loss. Our lead candidate, ALX-001, is a first-in-class, oral small molecule designed to block the degradation of synapses, the vital connections between neurons that are essential for memory and cognitive function. By preserving these connections, we aim to slow or even halt the progression of neurodegenerative diseases.

Our Pipeline

The Role of mGluR5 in Synapse Loss

Cellular Pathology of Disease

Upstream

Aβ oligomers accumulate decades before symptom onset.

Coupling

Aβ oligomers are neurotoxic and bind neurons via Cellular Prion Protein (PrPC) and activate the mGluR5 complex.

mGluR5 Signaling

Aβ oligomers activate a pathogenic signaling cascade on synapses.

Downstream

Synapses become dysfunctional. Tau pathology is activated. Immune system is recruited and synapses are lost.

Drugging the mGluR5 Cascade

ALX-001 (BMS-984923) is a silent allosteric modulator of the mGluR5 receptor, designed to block pathogenic activation while maintaining healthy glutamate signaling. By targeting these vital synapses, this oral molecule offers a path to selectively treating disease. Preclinical evidence confirms its role in protecting synaptic function against various harmful proteins.

Originally identified by Bristol Myers Squibb, its specific application for brain health was discovered by Yale's Dr. Stephen Strittmatter. Allyx Therapeutics now holds the exclusive global license to develop this breakthrough therapy for patients.